Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

US Patent 9765340 · Granted Sep 19, 2017

Estimated economic value: $6,611,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Back interface for rack shelf2025
Method for treating pruritus2025
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2023
Fixation members, assemblies, and related systems and methods2023
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2022
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2022
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2021
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2021
Transferrin/transferrin receptor-mediated siRNA delivery2018
Interfering RNA delivery system and uses thereof2018
Interfering RNA delivery system and uses thereof2017
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions2017